sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has submitted a Form 8.3 to the Irish Takeover Panel regarding its interests in Avadel Pharmaceuticals plc. As of December 31, 2025, The Vanguard Group holds 5,864,781 US$0.01 ordinary shares in Avadel, representing 6.02% of the company's relevant securities.
Recent activities include the purchase of 5,752 shares and the sale of 5,513 shares, both transactions occurred at a unit price of 21.55 USD. No positions in cash-settled or stock-settled derivatives have been reported. Furthermore, neither indemnity arrangements nor agreements related to securities options or derivatives have been disclosed.
This filing is in compliance with Rule 8.3 of the Irish Takeover Panel Act, 1997, as updated by the Takeover Rules of 2022, which mandates transparency for entities with significant stakes in publicly-listed companies.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.